Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Print1
- Calculators, Formulas, Algorithms1
- Article Type
- Research Support, U.S. Gov't, P.H.S.1
- Result From
- Lane Catalog1
- PubMed1
- SearchWorks (biomedical subset) 1
-
Year
- Journal Title
- Clin Pharmacol Ther1
Search Results
Sort by
year (new to old)
- DatabaseSummary: Provides detailed, evidence-based decision trees and a step-by-step approach, covering prevention, diagnosis, treatment and prognosis. Incorporates guidelines, systematic reviews from BMJ Clinical Evidence, and content from Cochrane Clinical Answers and AHFS Drug Information Essentials.Digital Access BMJ Database
- ArticleDi Carlo FJ, Leinweber FJ, Szpiech JM, Davidson IW.Clin Pharmacol Ther. 1977 Dec;22(6):858-63.The metabolism of l-bunolol, a new beta-blocking drug, was studied in man after single oral 3-mg doses of 3H-labeled compound. Absorption from the gut was rapid and virtually complete. Peak levels of bunolol and of dihydrobunolol, an active metabolite, were observed at 1 hr. Excretion of the administered radioactivity was mainly into the urine (78% in 4 days), with only 3% appearing in the feces. Bunolol, bunolol glucuronide, bunolol sulfate, dihydrobunolol, and dihydrobunolol glucuronide were identified and quantified in the plasma. These compounds represented 82% of the radioactivity in plasma at 30 min and 55% at 24 hr. Plasma half-lives (+/-S.D.) were estimated to be 6.1 +/- 0.3 hr for bunolol, 9.1 +/- 1.9 hr for bunolol glucuronide, 17.4 +/- 2.5 hr for bunolol sulfate, 7.1 +/- 0.5 hr for dihydrobunolol, and 7.7 +/- 0.8 hr for dihydrobunolol glucuronide.